Results 131 to 140 of about 4,861,637 (146)

SBRT for oligoprogressive oncogene addicted NSCLC

Lung Cancer, 2017
Lung cancer is one of the leading causes of cancer death in men and women and treatment outcome continues to lag behind other common cancer types. A subset of lung adenocarcinoma patients exhibit a somatic mutation in EGFR or an ALK rearrangement.
Matthias Guckenberger
exaly   +2 more sources

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer [PDF]

Journal of Thoracic Oncology, 2012
Introduction:Many patients with oncogene-driven non–small-cell lung cancer (NSCLC) treated with tyrosine kinase inhibitors experience limited sites of disease progression.
Gregory Gan, Robert C Doebele, Paul A Bunn   +2 more
exaly   +2 more sources

Local treatment for oligoprogressive metastatic sites of breast cancer: efficacy, toxicities and future perspectives

Clinical and Experimental Metastasis
Metastatic breast cancer (MBC) is still an incurable disease, which eventually develops resistance mechanisms against systemic therapies. While most patients experience widespread disease progression during systemic treatment (ST), in some cases ...
Ugo De Giorgi, Michela Palleschi, Giandomenico di Menna   +2 more
exaly   +2 more sources

Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions

Expert Review of Anticancer Therapy, 2020
Introduction: The aim of this paper was to perform a narrative review of the literature on the available approaches in the treatment of two emerging subpopulations of metastatic renal cell carcinoma (mRCC) patients: the oligometastatic disease (less than
Francesco Massari, Matteo Santoni, Maddalena Donini   +2 more
exaly   +2 more sources

Stereotactic Body Radiation Therapy for Oligoprogressive Disease in Androgen-Suppressed Prostate Cancer: Primary Endpoint Analysis of the TRAP Trial

International Journal of Radiation Oncology Biology Physics
PURPOSE: Optimal management of oligoprogressive prostate cancer while on androgen receptor pathway inhibitors (ARPIs) is not known. The TRAP trial tests the role of stereotactic body radiation therapy (SBRT) in this setting. The objective of this phase 2
Priyanka H Patel, Alison Tree, Fiona McDonald   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease

Acta Oncológica, 2022
Kara Schnarr, Anil Kapoor, Sebastien Hotte   +2 more
exaly  

Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer

European Urology Oncology, 2021
Samuel Denmeade, Kekoa Taparra, Phuoc T. Tran   +2 more
exaly  

Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective Trials

International Journal of Radiation Oncology Biology Physics, 2022
James Welsh, Vivek Verma
exaly  

People also looked at

Frontiers in Oncology, 2022
Shang-Jui Wang, Paul Monk, Dayssy A Diaz
exaly  

Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non–Small Cell Lung Cancer

Journal of Thoracic Oncology, 2017
Aparna Kesarwala, Udayan Guha, Arun Rajan   +2 more
exaly